Antibiofilm agent-21 

Antibiofilm agent-21 is an orally active prodrug of Antibiofilm agent-20 (HY-182268) with glucuronidation. Antibiofilm agent-21 avoids absorption in the small intestine via reduced membrane permeability, improving colon delivery rate, and converts to its active form in the colon. Antibiofilm agent-21 increases colon length and reduces IL-17 and TNF-α levels in a murine DSS (HY-116282C)-induced colitis model. Antibiofilm agent-21 can be used for the research of inflammatory bowel disease^[1].

Antibiofilm agent-21 (Compound 3) weakly inhibit Escherichia coli biofilm formation (IC₅₀ >100 μg/mL) and exhibits antibacterial activity against Escherichia coli (MIC >128 μg/mL)^[1].
Antibiofilm agent-21 has improved solubility, very low membrane permeability, and high metabolic stability (82% remaining after 30 min in mouse liver microsomes)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antibiofilm agent-21 (Compound 3) (30-100 mg/kg; p.o.; once daily; 7 consecutive days) significantly increases colon length and reduces colonic inflammatory cytokine levels in a murine DSS (HY-116282C)-induced colitis model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

567.67

C₃₁H₄₁N₃O₇

O=C(O)[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@H]1OC(C=C2CNC3=NC=CN3CC(C=C4)=CC=C4CCCC)=C(C=C2)CCCC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shimizu T,et al. Discovery of a Colon-Targeted Prodrug As an Escherichia coli Biofilm Inhibitor for Treating Inflammatory Bowel Disease[J]. ACS Medicinal Chemistry Letters, 2026.